• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Canada
  • United Kingdom
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Coronavirus > 5 things to know in life sciences: Week of Feb. 15

5 things to know in life sciences: Week of Feb. 15

Feb. 19, 2021 by Steve Kemler, Adam Lohr and David Stuart

  • email
  • Twitter
  • Facebook
  • Linkedin

In this week’s roundup we look at promising results in a clinical trial leveraging an existing diabetes drug for the treatment of obesity, a new and less invasive treatment for sleep apnea, and a new technology in cardiac catheters. We also examine the impact of the pandemic on oncology trials and the challenges of developing new treatments for Alzheimer’s disease.

Each week, we highlight five things you need to know about in the life sciences industry. Here’s the latest.

An encouraging move in the fight against obesity

On Feb. 10, Novo Nordisk released Phase III data on its latest obesity drug that showed one third of patients “lost more than 20% of their body weight during the 68-week trial,” with the average participant losing more than 33 pounds, and improvement in chronic risk measures. This drug is currently marketed as Ozempic and is used to treat diabetes. Now, as the Fierce Pharma piece linked above explains, Novo Nordisk is testing the drug under the name semaglutide (in higher dosage quantities) for the specific treatment of obesity. The company expects a decision from the FDA about whether the drug can be marketed to treat obesity by mid-2021.

The prevalence of obesity in U.S. adults was 42% between 2017 and 2018, according to the CDC, and the “estimated annual medical cost of obesity in the United States was $147 billion in 2008 US dollars.” Heart disease, diabetes, sleep apnea, and some forms of cancer are just a few of the catalysts in the search for the holy grail of a safe and effective weight loss drug.

Cancer trials take a hit from pandemic as global studies dropped by 60%

There was a 60% reduction in new oncology trials globally during the first wave of the COVID-19 pandemic (from January to May 2020), according to new study using data from Medidata and published by the JAMA network. This drop will likely delay and in some cases stop the development of many new cancer therapies. More broadly, the results of the study raise concerns that the decrease in trial launches will likely have a significant, lingering impact on scientific research for other diseases as well.

MedLumics raises $21.8M to test its optically guided heart ablation catheter

Medical device company MedLumics will use a recent fundraising round to move from preclinical development to the company’s first-in-human clinical tests for its heart ablation catheter, according to this Fierce Biotech piece. The technology has the potential to help people with atrial fibrillation (AF), a serious heart condition that causes an irregular heartbeat. The minimally invasive technique uses light to accurately identify the ablation lesions that cause AF and then destroy the tissue causing arrhythmia.

MedLumics has said that “recurrence of AF after catheter ablation is currently high, with 20% of patients needing a repeat procedure within a year,” according to this article in Pharmaphorum. If successful, MedLumics’ new procedure will significantly improve results and reduce the need for a repeat procedure. Some estimates suggest the market for catheter ablation of AF could be as high as $1 billion a year.

FDA OKs first daytime use device for snoring and sleep apnea

Last week, the FDA approved a new daytime use device for patients with mild cases of sleep apnea, an encouraging development for sleep apnea patients looking for an alternative to more disruptive masks and CPAP machines that can only be used at night. The new device delivers electrical stimulation to train the patient’s tongue to avoid blocking the airway while sleeping.

While obstructive sleep apnea may be a risk factor for severe COVID-19 cases, the disease on its own can cause serious problems such as heart attacks, glaucoma, diabetes and more, according to the FDA. Sleep apnea afflicts over 20% of obese adults, according to a pulmonary and sleep medicine specialist at Johns Hopkins, and more than 40% of adults are clinically obese.

Effective new treatments for Alzheimer’s disease remain elusive

Successfully bringing new, effective treatments to market for Alzheimer’s Disease has always been a challenging proposition. This week, Cortexyme was reminded of this when its GAIN trial was put on a partial hold by the FDA. This partial hold means the company will halt enrolling new patients, though existing patients will continue to receive their assigned doses until they reach the trial’s one-year end-point. Although the adverse events that caused the hold represent a setback for Cortexyme, they were reversible and the company remains optimistic that the trial overall will meet its endpoints.

In photos: A photographer documents his father’s losing battle with Alzheimer’s and confronts his likely fate.

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • 5 things to know in life sciences: Week of Feb. 1

    This week, we look at mRNA drug manufacturing capacity, gene therapy investments, news of a new FDA role dedicated to medical device cybersecurity, and more.

  • 5 things to know in life sciences: Week of Feb. 8

    Recent industry news includes the impact of new COVID-19 variants on existing vaccines for the disease, the outlook for drug pricing reforms under the Biden administration, and the promise of 3D-printed hearts.

  • 5 things to know this week in life sciences: Week of Jan. 11

    News this week included Bluebird Bio’s announcement about splitting into two companies, the promise of quantum computing in drug design, and how mRNA platforms offer promise for diseases beyond COVID-19.

Filed Under: Coronavirus, Life Sciences Tagged With: biotech, clinical trials, drug development, life sciences

About Steve Kemler

Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.

As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional life sciences initiatives.

In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

About Adam Lohr

Adam is an audit partner and life sciences senior analyst in RSM's cutting-edge industry eminence program. In addition to providing assurance services to his clients, he sits on RSM’s national life science team and leads the San Diego office life science practice.

His senior analyst responsibilities include advising the firm’s life sciences care clients and client servers as they work to navigate the rapidly changing industry environment. Adam regularly writes, presents and advises on capital markets, digital transformation, policy and other issues transforming life sciences. He is an instructor at the regional and national level, and is experienced in the application of ASC 606 revenue recognition for the technology and consumer products industries.

Adam has over 12 years of accounting and finance experience, serving private equity-backed and private closely held companies in the middle market. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their business.

About David Stuart

David has more than eight years of corporate finance and capital markets experience supporting debt and equity transactions for various industries including technology, telecommunications, life sciences, renewable energy and consumer products. His experience includes negotiating and facilitating transaction closings for private equity, venture capital and financial institutions across North America.

In May 2020, David was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

Primary Sidebar

Other Regions

  • Canada
  • United Kingdom

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Life Science articles

5 things to know in life sciences: Week of March 1

Mar. 4, 2021

5 things to know in life sciences: Week of Feb. 22

Feb. 26, 2021

5 things to know in life sciences: Week of Feb. 15

Feb. 19, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences